Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Ovarian Cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    729 result(s) found for: Ovarian Cancer. Displaying page 7 of 37.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    EudraCT Number: 2009-015082-31 Sponsor Protocol Number: M10-757 Start Date*: 2010-04-07
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: A Phase 2 Randomized Clinical Trial of ABT-888 in Combination with Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Subjects with Recurrent High Grade Serous Ovarian Cancer
    Medical condition: Recurrent high grade serous ovarian cancer.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2004-005276-16 Sponsor Protocol Number: ET743-OVA-301 Start Date*: 2005-10-27
    Sponsor Name:Pharma Mar S.A.
    Full Title: An open-label multicenter randomized Phase 3 study comparing the combination of DOXIL®/CAELYX® and YONDELIS® with DOXIL®/CAELYX® alone in subjects with advanced relapsed ovarian cancer.
    Medical condition: Advanced relapsed ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033130 Ovarian cancer NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) SE (Completed) DE (Completed) ES (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-005557-38 Sponsor Protocol Number: D4200C00083 Start Date*: 2009-12-29
    Sponsor Name:AstraZeneca GmbH
    Full Title: Addition of vandetanib to standard therapy (pegliposomal doxorubicin) in patients with recurrent ovarian cancer. A multi-centre, non-randomized, open phase I/randomized phase II study
    Medical condition: Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033128 Ovarian cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-010095-23 Sponsor Protocol Number: AA-GYN-002 Start Date*: 2009-07-06
    Sponsor Name:Omrix Biopharmaceuticals Ltd
    Full Title: A prospective, controlled, randomized, multi-center, pivotal study evaluating the safety and efficacy of ADHEXIL in prevention and/or reduction of adhesions in gynecology surgery
    Medical condition: Adhesions in gynecology surgery. Surgeries involved will be ovarian cystectomy, endometriosis, inflammation, adhesiolysis Ovarian adhesion MedDRA 10067156 Tubal rupture MedDRA 10067553
    Disease: Version SOC Term Classification Code Term Level
    9.1 10014778 Endometriosis LLT
    9.1 10004433 Benign ovarian tumour LLT
    9.1 10053865 Benign fallopian tube neoplasm LLT
    9.1 10050697 Fallopian tube cyst LLT
    9.1 10061855 Fallopian tube neoplasm LLT
    9.1 10048991 Ovarian adenoma LLT
    9.1 10033132 Ovarian cyst LLT
    9.1 10033136 Ovarian cyst ruptured LLT
    9.1 10064257 Ovarian fibroma LLT
    9.1 10033236 Ovarian germ cell teratoma benign LLT
    9.1 10061535 Ovarian neoplasm LLT
    9.1 10052456 Parovarian cyst LLT
    9.1 10036049 Polycystic ovaries LLT
    9.1 10033139 Ovarian disorder LLT
    9.1 10033263 Ovarian haematoma LLT
    9.1 10065741 Ovarian haemorrhage LLT
    9.1 10058823 Ovarian mass LLT
    9.1 10033277 Ovarian prolapse LLT
    9.1 10033279 Ovarian rupture LLT
    9.1 10046988 Varicocele ovarian LLT
    9.1 10052094 Fallopian tube disorder LLT
    9.1 10065789 Fallopian tube obstruction LLT
    9.1 10065790 Fallopian tube perforation LLT
    9.1 10065791 Fallopian tube stenosis LLT
    9.1 10050468 Haematosalpinx LLT
    9.1 10061071 Congenital ovarian anomaly LLT
    9.1 10061062 Congenital fallopian tube anomaly LLT
    11.1 10067156 PT
    9.1 10060781 Haemorrhagic ovarian cyst LLT
    11.1 10067553 PT
    9.1 10033157 Ovarian enlargement LLT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-003772-35 Sponsor Protocol Number: AURA-6202-006 Start Date*: 2007-09-09
    Sponsor Name:Nerviano Medical Sciences S.r.l.
    Full Title: Phase II study of PHA-739358 administered by a 24-hour IV infusion every 14 days in advanced/metastatic breast, ovarian, colorectal, pancreatic, small cell lung and non small cell lung cancers.
    Medical condition: Advanced/metastatic breast, ovarian, colorectal, pancreatic, small cell lung, non small cell lung and squamous non small cell lung cancers.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027475 Metastatic breast cancer LLT
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059515 Non-small cell lung cancer metastatic PT
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10059514 Small cell lung cancer metastatic PT
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033610 Pancreatic carcinoma metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) IT (Completed) FR (Completed) NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003472-52 Sponsor Protocol Number: YO39523 Start Date*: 2017-07-21
    Sponsor Name:Roche Farma S.A.U que realiza el ensayo en España y que actúa como representante de F.Hoffmann-La Roche Ltd.
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB VERSUS PLACEBO ADMINISTERED IN COMBINATION WITH PACLITAXEL, CARBOPLATIN, AND BEVACIZUMAB TO PATIENTS WITH NEWLY-DIAGNOSED STAGE III OR STA...
    Medical condition: Ovarian cancer, fallopian tube cancer, primary peritoneal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) SE (Completed) NO (Completed) CZ (Completed) DE (Completed) AT (Completed) PL (Completed) FI (Completed) GR (Prematurely Ended) DK (Completed) FR (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-003929-22 Sponsor Protocol Number: ICON7 Start Date*: 2006-12-15
    Sponsor Name:Medical Research Council
    Full Title: ICON7 - A randomised, two-arm, multicentre Gynaecologic Cancer InterGroup trial of adding bevacizumab to standard chemotherapy (carboplatin and paclitaxel) in patients with epithelial ovarian cancer.
    Medical condition: Following initial surgery (either debulking cytoreductive surgery or a biopsy if the patient has FIGO stage IV disease and there is no planned surgery before disease progression) patients with new...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10033128 Ovarian cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) FI (Completed) DE (Completed) DK (Completed) SE (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-005971-17 Sponsor Protocol Number: H8K-MC-JZAG Start Date*: 2007-03-27
    Sponsor Name:ELI LILLY
    Full Title: A Phase 2 Study of LY573636 as Treatment for Patients with Platinum-Resistant Ovarian Cancer Protocol H8K-MC-JZAG
    Medical condition: patients with epithelial ovarian cancer who have received no more than 2 prior systemic treatment regimens for platinum-resistant disease.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10061328 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-001551-22 Sponsor Protocol Number: TRIO 014 Start Date*: 2008-10-21
    Sponsor Name:Cancer International Research Group
    Full Title: A randomized, double-blind, placebo controlled, multicenter, phase II study of adding AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R) to first...
    Medical condition: Optimally debulked epithelial ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033128 Ovarian cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) DE (Completed) ES (Completed) IE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-003792-63 Sponsor Protocol Number: UCL/17/0629 Start Date*: 2018-10-23
    Sponsor Name:University College London
    Full Title: Phase II trial of maintenance pembrolizumab following weekly paclitaxel for recurrent ovarian, fallopian tube or peritoneal cancer
    Medical condition: recurrent ovarian/fallopian tube or primary non-mucinous peritoneal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2005-001875-37 Sponsor Protocol Number: AK/RH/22498/1 Start Date*: 2007-08-24
    Sponsor Name:University of Warwick
    Full Title: Neo-ESCAPE (Neoadjuvant Extended Sequential Chemotherapy with Adjuvant Postoperative treatment for Epithelial non-mucinous advanced inoperable peritoneal malignancy): a randomised feasibility study...
    Medical condition: Epithelial non-mucinous advanced inoperable peritoneal malignancy (ovarian carcinoma, ovarian carcinosarcoma, fallopian tube or primary peritoneal carcinoma)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033128 Ovarian cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-000293-29 Sponsor Protocol Number: ICR-CTSU/2012/10038 Start Date*: 2014-01-17
    Sponsor Name:The Royal Marsden NHS Foundation Trust [...]
    1. The Royal Marsden NHS Foundation Trust
    2. The Institute of Cancer Research
    Full Title: A prospective, multi-centre, open label, non-randomised two stage phase II clinical trial evaluating the efficacy of abiraterone in patients with epithelial ovarian (including fallopian tube and pr...
    Medical condition: Epithelial ovarian cancer (including fallopian tube and primary peritoneal)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061328 Ovarian epithelial cancer PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2008-006831-10 Sponsor Protocol Number: 1199.15 Start Date*: Information not available in EudraCT
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: Multicenter, randomised, double-blind Phase III trial to investigate the efficacy and safety of BIBF 1120 in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and pac...
    Medical condition: Advanced ovarian cancer, fallopian tube cancer or primary peritoneal cancer
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026469 Malignant neoplasm of specified parts of peritoneum LLT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10026340 Malignant neoplasm of peritoneum, unspecified LLT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) FR (Completed) SE (Completed) BE (Completed) PT (Completed) SK (Completed) DK (Completed) AT (Completed) NL (Completed) FI (Completed) PL (Completed) IT (Completed) GR (Completed) CZ (Completed) ES (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2010-024305-13 Sponsor Protocol Number: QPT-ORE-02 Start Date*: 2011-03-15
    Sponsor Name:QUEST PHARMATECH INC.
    Full Title: A RANDOMIZED CONTROLLED STUDY ON THE EFFECTIVENESS OF FIRST-LINE CHEMOTHERAPY (CARBOPLATIN AND PACLITAXEL) VERSUS CHEMO-IMMUNOTHERAPY (CARBOPLATIN-PACLITAXEL-OREGOVOMAB) IN PATIENTS WITH ADVANCED E...
    Medical condition: Advanced Epithelial Ovarian, Adnexal or Peritoneal Carcinoma.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-002411-14 Sponsor Protocol Number: 12576/15 Start Date*: 2015-07-28
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: TRABECTEDIN SINGLE AGENT IN PARTIALLY PLATINUM SENSITIVE (PPS) RECURRENT OVARIAN CANCER (ROC) PATIENTS: A PROSPECTIVE, PHASE II STUDY
    Medical condition: ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10051938 Ovarian adenocarcinoma LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-005153-12 Sponsor Protocol Number: MITO26 Start Date*: 2019-07-17
    Sponsor Name:FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE
    Full Title: Phase II trial on trabectedin in the treatment of advanced uterine and ovarian carcinosarcoma (Cs) – MITO 26
    Medical condition: advanced ovarian and uterine carcinosarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10052204 Ovarian carcinosarcoma LLT
    20.0 100000004864 10007508 Carcinosarcoma uterus LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003346-90 Sponsor Protocol Number: D0816C00014 Start Date*: 2017-04-05
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase IIIb, Randomised, Double-blind, Placebo-controlled, Multicentre Study of Olaparib Maintenance Retreatment in Patients with Epithelial Ovarian Cancer Previously Treated With a PARPi and Res...
    Medical condition: Epithelian ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) PL (Completed) BE (Completed) DE (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-005027-37 Sponsor Protocol Number: MK3475-B96/ENGOT-ov65 Start Date*: 2022-01-07
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Paclitaxel With or Without Bevacizumab for the Treatment of Platinum-resistant Recurrent Ovarian Cancer...
    Medical condition: Platinum-resistant Recurrent Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NO (Trial now transitioned) FI (Trial now transitioned) IT (Trial now transitioned) DK (Trial now transitioned) PL (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003871-32 Sponsor Protocol Number: AL3818-US-002 Start Date*: 2021-11-11
    Sponsor Name:ADVENCHEN LABORATORIES, LLC
    Full Title: A Phase 1/2a/3 Evaluation of the Safety and Efficacy of Adding AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects...
    Medical condition: Recurrent or metastatic endometrial, ovarian, fallopian tube, primary peritoneal, or cervical carcinoma.
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014734 Endometrial cancer metastatic PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014736 Endometrial cancer recurrent PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057529 Ovarian cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005990-29 Sponsor Protocol Number: ENGOT-OV64/NSGO-CTU-SOLERO Start Date*: 2021-12-14
    Sponsor Name:Nordic Society of Gynaecological Oncology - Clinical Trial Unit (NSGO-CTU)
    Full Title: An Early Phase Randomized Trial of APX005M in BRCAwt Patients with Recurrent Ovarian Cancer
    Medical condition: Patients with histologically diagnosed epithelial ovarian, fallopian tube or primary peritoneal cancer with radiologically or histologically confirmation of relapsed disease, and with known BRCA wi...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    20.1 10022891 - Investigations 10080244 Peritoneal cancer index PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Prematurely Ended) DK (Prematurely Ended) NO (Prematurely Ended) FI (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 3  4  5  6  7  8  9  10  11  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 05:29:40 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA